News

Filter

Current filters:

Gilead SciencesGlobal

1 to 9 of 10 results

New treatments to boost hepatitis C market to $19.2 billion by 2016

New treatments to boost hepatitis C market to $19.2 billion by 2016

24-06-2014

The launch of interferon-free regimens is expected to boost the hepatitis C market from $2.9 billion…

Anti-viralsAntiviralsBusiness FinanceCytokinesDatamonitorGilead SciencesGlobalMajorMarkets & MarketingPharmaceuticalSovaldi

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top